

ALL. B

Decreto Rettore Università di Roma "La Sapienza" n 3103/2021 del 24-11-2021

**ANNA COPPA**

Curriculum Vitae

Roma, 8-12-2021

**Part I – General Information**

Full Name	Anna Coppa
Date of Birth	
Place of Birth	
Citizenship	
Permanent Address	
Mobile Phone Number	
E-mail	
Spoken Languages	Italiano-Inglese

**Part II – Education**

Type	Year	Institution	Notes (Degree, Experience,...)
Titolo di Studio	1980	Università degli Studi Federico II Napoli	Laurea in Medicina e Chirurgia
Titolo di Abilitazione	1981	Università degli Studi Federico II Napoli	Abilitazione Esercizio della professione di Medico Chirurgo
Specializzazione	1983	Università degli Studi Federico II Napoli	Endocrinologia
Specializzaione	1987	Università degli Studi Federico II Napoli	Patologia Generale
Titolo di Abilitazione	2018	ANVUR	Abilitazione Scientifica Nazionale per professore di II fascia SC06/A2- SSD MED/04

**Part III – Appointments**

IIIA – Academic Appointments

Start	End	Institution	Position
1990	1992	Dipartimento di Biologia e Patologia Cellulare e Molecolare dell'Università "Federico II" di Napoli	Collaboratore tecnico laureato
1992	2001	Dipartimento di Medicina Sperimentale Università degli Studi Sapienza, Roma	Collaboratore tecnico laureato
2001	oggi	Dipartimento di Medicina Sperimentale Università degli Studi Sapienza, Roma	Ricercatore confermato
2008	2011	Facoltà di Medicina e Odontoiatria, Università degli Studi Sapienza, Roma	Membro della Commissione Percorso Qualità
2011	oggi	Facoltà di Medicina e Odontoiatria, Università degli Studi Sapienza, Roma CCLTNPEE	Membro della Commissione Percorso Qualità
2008	2015	Dipartimento di Medicina Sperimentale Università degli Studi Sapienza, Roma	Membro della Giunta di Dipartimento
2011	2018	MIUR	Membro dell'Albo dei Revisori di Progetti di Ricerca del MIUR

IIIB – Other Appointments

Start	End	Institution	Position
1990	1992	S.S. di Diagnostica Endocrinologica di Laboratorio d'Università "Federico II" Napoli	Dirigente medico di primo livello a tempo pieno
1992	2000	Servizio di Immunopatologia Dipartimento di Medicina Sperimentale, Università Sapienza Roma	Dirigente medico di primo livello
2000	2005	Servizio di Collagenopatie Prev. Tratt. Amb. Malattie Reumatiche Dipartimento di Medicina	Dirigente medico di primo livello

		Sperimentale, Università Sapienza Roma.	
2005	oggi	UOSD Oncologia Molecolare, DAI Medicina Diagnostica e Radiologia, AOU-Policlinico Umberto I Roma	Dirigente medico di primo livello
2.1.2012	30.9.2012	Hilman Cancer Center University of Pittsburg, DNA Repair Laboratory	Visiting Scholar
1.7.1997	31.8.1997	Department of Anatomy and Cell Biology, University of Toronto	Medical Visiting fellow
1.8.1995	30.11.1995	National Institute of Diabetes and Digestive and Kidney (NIDDK), NIH Bethesda	Special volunteer

#### Part IV – Teaching experience

Year	Institution	Lecture/Course
2000 ad oggi	CLM “B” Facoltà di Medicina e Odontoiatria Università degli Studi Sapienza, Roma	Patologia e Fisiopatologia Generale I e II
2000 ad oggi	TPNEE Facoltà di Medicina e Odontoiatria Università degli Studi Sapienza Roma	Patologia Generale e Fisiopatologia
2011 ad oggi	Facoltà di Medicina e Odontoiatria dell’Università degli Studi Sapienza, Roma	Tutor per gli studenti del CLMB
2014-15	Università degli Studi Sapienza, Roma	Docente del Dottorato in Medicina Molecolare

#### Part V - Society memberships, Awards and Honors

Year	Title
2002 ad oggi	Membro della Società Italiana di Cancerologia (SIC)
2002 ad oggi	Membro della Società “European Association for Cancer Research” (EACR)
2006-12	Membro della Società Italiana per la Biomedicina e Biotecnologie Spaziali (ISSBB)

#### Part VI - Funding Information [grants as PI-principal investigator or I-investigator]

##### Ultimi 10 anni

Year	Title	Program	Grant value
2021-23	<i>Dissecting new functions of the Nijmegen breakage syndrome gene in cerebellar development</i>	Telethon Grant 2020	€ 239.250 [I]
2021-25	<i>Dissecting unconventional replication stress responses to unravel new vulnerabilities of MYCN-driven tumors</i>	AIRC Investigator Grant 2020	€ 1.154.000 [I]
2020	<i>Analysis of Tumor Mutational Burden in Male Breast Cancers characterized for germline mutations in homologous recombination genes</i>	Progetti medi dell’Università degli Studi Sapienza	€ 10.000 [I]
2019	<i>New players in the Homologous Recombination pathway: investigating the role of SMYD3 in breast cancers characterized for BRCA mutation status</i>	Progetti medi dell’Università degli Studi Sapienza	€ 10.000 [I]
2018-20	<i>Harnessing replication stress to understand and tackle MYCN-dependent tumors</i>	Istituto Pasteur – Fondazione Cenci Bolognetti Programmi di Ricerca “Anna Tramontano”	€ 60.000 [I]
2018	<i>Providing insights into the transcriptome profile of BRCA mutation-positive and -negative male breast cancer</i>	Progetti medi dell’Università degli Studi Sapienza	€ 10.000 [I]
2017	<i>Exploring the transcriptional landscape of BRCA-positive and BRCA-negative male breast cancers by RNA-sequencing</i>	Progetti medi dell’Università degli Studi Sapienza	€ 14.000 [I]
2016	<i>Genomic screening of BRCA1/2 mutation negative Italian male breast cancers by gene-panel sequencing</i>	Progetti medi dell’Università degli Studi Sapienza	€ 14.000 [I]
2016-19	<i>The MRN complex and PARP: targeting the replication stress response in MYCN dependent neuronal tumors</i>	AIRC Investigator Grant 2015	€ 377.000 [I]

2015-17	<i>Insights into the functions of DNA damage processing and repair factors to design novel selective anticancer drugs</i>	MIUR-PRIN 2015	€ 50.000 [I]
2015	<i>Applicazione del Next Generation Sequencing (NGS) per l'identificazione di alterazioni genetiche nei tumori ereditari"</i>	Progetti piccoli dell'Università degli Studi Sapienza	€ 4.000 [PI]
2014-15	<i>Uncovering the functional links between MYCN and the MRN complex to understand the phenotypic overlap between Nijmegen Breakage syndrome and Feingold syndrome</i>	Progetti di Ateneo dell'Università degli Studi Sapienza	€ 53.000 [I]
2013	<i>Storia molecolare delle neoplasie: caratterizzazione delle alterazioni genetiche ed epigenetiche attraverso "Next Generation Sequencing"</i>	Progetti di Ateneo dell'Università degli Studi Sapienza	€ 3000 + 22946 AR [I]
2012	<i>Development of new therapeutic strategies based on cancer proteomics analysis of signal transduction pathways important in brain tumor stem cells</i>	Progetti di Ateneo dell'Università degli Studi Sapienza	€ 64.000 [I]
2010-11	<i>Hedgehog signaling regulatory networks in brain cancer stem cells</i>	Progetti di Ateneo dell'Università degli Studi Sapienza	€ 80.000 [I]
2009-11	<i>Molecular Control of circadian rhythms during space flight (MOCC)</i>	Biotechnology for human space exploration (ASI)	€ 127.500 [PI]

## Part VII – Research Activities

### Keywords

### Brief Description

NGS, Lung ca., Colon ca, Multiple primary lung cancers, Precision medicine	1) Nuovi approcci tecnologici nel campo dell'oncologia molecolare: il "next generation sequencing" nella diagnostica dei tumori ereditari e dei tumori solidi
BRCA, breast ca, ovarian ca, VUS, splice variant, male breast cancer, transcriptome profiling, molecular subtypes, breast cancer susceptibility	2) Genetica molecolare delle neoplasie della mammella, ovaio e dei tumori della mammella maschile
DNA damage response, MYCN, neuroblastoma, PARP expression, PARP inhibitors	3) Ruolo del DNA damage response nella cancerogenesi
PRDX2, Circadian rhythm, metabolic clock; PRDX1, PRDX6, BRAF V600E, papillary thyroid ca	4) Peroxiredoxine e ritmo circadiano; peroxiredoxine e cancro della tiroidea
FRTL5, cell growth, TGFb, TGFb receptors, SMAD2, SMAD4	5) Fisiopatologia della crescita e sopravvivenza delle cellule tiroide: ruolo del TGF-beta e della sua via di segnale
Thyroid ca, PI3K, signal transduction, KRAS, Cell migration, motility and/or invasion, EMT	6) Ruolo delle alterazioni di K-Ras, della PI3K nel controllo del potenziale invasivo di cellule trasformate (mammella, tiroide).

## Part VIII – Summary of Scientific Achievements

Product type	Number	Data Base	Start	End
Papers [international]	46	SCOPUS	1995	2021
Papers [international]	40	WOS Author ID: N-3274-2016	1995	2021

	SCOPUS	WOS
Total Impact factor	188,306	188,306

Average Impact factor per product	4,09	4,09
Total Citations	798	695
Average Citations per Product	17,34	17,37
Average Citations per year	30,69	26,7
Hirsch (H) index	18	18
Normalized H index*	0,69	0,69

\*H index divided by the academic seniority.

## Part IX– Selected Publications

List of the publications selected for the evaluation. For each publication report title, authors, reference data, journal IF (if applicable), citations, press/media release (if any).

- Di Giulio S, Colicchia V, Pastorino F, Pedretti F, Fabretti , Nicolis di Robilant V, Ramponi V, ScafettaV, Moretti M, Licursi V, Belardinilli F, Peruzzi G, Infante P, Goffredo *BM*, **Coppa A**, Canettieri G, Bartolazzi A, Ponzoni M, Giannini G and Petroni M. *A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors*. **Oncogene** 2021; doi.org/10.1038/s41388-021-02003-0. PMID: 34508175  
[WOS] Journal Impact Factor 2020: **9,867** citations no: **0**  
[Scopus] citations no: **0**
- Barnes DR, Silvestri V, Leslie G, McGuffog L, Dennis J, Yang X, Adlard J, Agnarsson BA, Ahmed M, Aittomäki K, Andrulis IL, Arason A, Arnold N, Auber B, Azzollini J, Balmaña J, Barkardottir RB, Barrowdale D, Barwell J, Belotti M, Benitez J, Berthet P, Boonen SE, Borg Å, Bozsik A, Brady A, Brennan P, Brewer C, Brunet J, Bucalo A, Buys SS, Caldés T, Caligo MA, Campbell I, Cassingham H, Lotte Christensen L, Cini G, Claes KBM; GEMO Study Collaborators; EMBRACE Collaborators, Cook J, **Coppa A**, Cortesi L, Damante G...et al. *Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores*. **J Natl Cancer Inst**. 2021 Jul 28:djab147. doi: 10.1093/jnci/djab147. Online ahead of print  
[WOS] Journal Impact Factor 2021: **13,5** citations no:**0**  
[Scopus] citations no: **0**
- Belardinilli F, Capalbo C, Malapelle U, Pisapia P, Raimondo D, Milanetti E, Yasaman M, Liccardi C, Paci P, Sibilio P, Pepe F, Bonfiglio C, Mezi S, Magri V, **Coppa A**, Nicolussi A, Gradilone A, Petroni M, Di Giulio S, Fabretti F, Infante P, Coni S, Canettieri G, Troncone G, Giannini G. *Clinical multigene panel sequencing identifies distinct mutational association patterns in metastatic colorectal*. **Front Oncol**. 2020 May 7;10:560. doi: 10.3389/fonc.2020.00560. PMID: 32457828.  
[WOS] Journal Impact Factor 2020: **6,24** citations no:-  
[Scopus] citations no: **5**
- Nicolussi A, Belardinilli F, Silvestri V, Mahdavian Y, Valentini V, D'Inzeo S, Petroni M, Zani M, Ferraro S, Di Giulio S, Fabretti F, Fratini B, Gradilone A, Ottini L, Giannini G, **Coppa A\***, Capalbo C\*. *Identification of novel BRCA1 large genomic rearrangements by a computational algorithm of amplicon-based Next-Generation Sequencing data*. **Peer J**. 2019 Nov 15;7:e7972. doi: 10.7717/peerj.7972. eCollection 2019. PMID: 31741787.  
\*corresponding authors  
[WOS] Journal Impact Factor 2019: **2,379** citations no: **1**  
[Scopus] citations no:**1**
- Nicolussi A, Belardinilli F, Mahdavian Y, Colicchia V, D'Inzeo S, Petroni M, Zani M, Ferraro S, Valentini V, Ottini L, Giannini G, Capalbo C and **Coppa A**. *Next-generation sequencing of BRCA1 and BRCA2 genes for rapid detection of germline mutations in hereditary breast/ovarian cancer* **Peer J**. 7 (2019): e6661 DOI 10.7717/peerj.6661 PMID: 31065452  
[WOS] Journal Impact Factor 2019: **2,379** citations no: **6**  
[Scopus] citations no: **9**
- Capalbo C, Belardinilli F, Raimondo D, Milanetti E, Malapelle U, Pisapia P, Magri V, Prete A, Pecorari S, Colella M, **Coppa A**, Bonfiglio C, Nicolussi A, Valentini V, Tessitore A, Cardinali B, Petroni M, Infante P, Santoni M, Filetti M, Colicchia V, Paci P, Mezi S, Longo F, Cortesi E, Marchetti P, Troncone G, Bellavia D, Canettieri G, Giannini G. *A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal Cancer*. **Cancers** (Basel). 2019 Jan 27;11(2). pii: E147. doi: 10.3390/cancers11020147. PMID: 30691222  
[WOS] Journal Impact Factor 2019: **6,126** citations no: **7**  
[Scopus] citations no: **7**
- Coppa A**, Nicolussi A, D'Inzeo S, Capalbo C, Belardinilli F, Colicchia V, Petroni M, Zani M, Ferraro S, Rinaldi C, Buffone A, Bartolazzi A, Screpanti I, Ottini L, Giannini G. *Optimizing the identification of risk-relevant mutations by multigene*

panel testing in selected hereditary breast/ovarian cancer families. *Cancer Med.* 2017 Dec 22. doi: 10.1002/cam4.1251. [Epub ahead of print] PMID: 29271107  
[WOS] Journal Impact Factor 2017: **3,202** citations no: **12**  
[Scopus] citations no: **13**

8. **Coppa A**, Buffone A, Capalbo C, Nicolussi A, D'Inzeo S, Belardinilli F, Colicchia V, Petroni M, Granato T, Midulla C, Zani M, Ferraro S, Screpanti I, Gulino A, Giannini G. *Novel and recurrent BRCA2 mutations in Italian breast/ovarian cancer families widen the ovarian cancer cluster region boundaries to exons 13 and 14.* **Breast Cancer Res Treat.** 2014 Dec;148(3):629-35. doi: 10.1007/s10549-014-3196-z. Epub 2014 Nov 14 PMID: 25395318.  
[WOS] Journal Impact Factor 2014: **3,940** citations no: **6**  
[Scopus] citations no: **7**
9. Nicolussi A, D'Inzeo S, Mincione G, Buffone A, Di Marcantonio MC, Cotellese R, Cichella A, Capalbo C, Di Gioia C, Nardi F, Giannini G, **Coppa A**. *PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms.* **Int J Oncol.** 2014 Feb;44(2):548-56. doi: 10.3892/ijo.2013.2208. Epub 2013 Dec 5. PMID: 24316730.  
[WOS] Journal Impact Factor 2014: **3,025** citations no: **22**  
[Scopus] citations no: **21**
10. D'Inzeo S, Nicolussi A, Donini CF, Zani M, Mancini P, Nardi F, **Coppa A**. *A novel human Smad4 mutation is involved in papillary thyroid carcinoma progression.* **Endocr Relat Cancer.** 2012 2012 Jan 9;19(1):39-55. doi: 10.1530/ERC-11-0233. Print 2012 Feb. PMID: 22109972.  
[WOS] Journal Impact Factor 2012: **5,261** citations no:**18**  
[Scopus] citations no: **19**
11. D'Inzeo S, Nicolussi A, Ricci A, Mancini P, Porcellini A, Nardi F, **Coppa A**. *Role of reduced expression of SMAD4 in papillary thyroid carcinoma.* **J Mol Endocrinol.** 2010 Oct;45(4):229-44. doi: 10.1677/JME-10-0044. PMID: 20685810  
[WOS] Journal Impact Factor 2010: **3,628** citations no:**18**  
[Scopus] citations no: **21**
12. Lazzereschi D, Nardi F, Turco A, Ottini L, D'Amico C, Mariani-Costantini R, Gulino A, **Coppa A**. *A complex pattern of mutations and abnormal splicing of Smad4 is present in thyroid tumours.* **Oncogene** 2005 Aug 11;24(34):5344-54 doi: 10.1038/sj.onc.1208603. PMID: 15940269.  
[WOS] Journal Impact Factor 2005: **6,872** citations no: **38**  
[Scopus] citations no: **40**

## All publication

- Di Giulio S, Colicchia V, Pastorino F, Pedretti F, Fabretti , Nicolis di Robilant V, Ramponi V, ScafettaV, Moretti M, Licursi V, Belardinilli F, Peruzzi G, Infante P, Goffredo BM, **Coppa A**, Canettieri G, Bartolazzi A, Ponzoni M, Giannini G and Petroni M. *A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors.* **Oncogene** 2021; doi.org/10.1038/s41388-021-02003-0. PMID: 34508175  
[WOS] Journal Impact Factor 2020: **9,867** citatios no: **0**  
[Scopus] citatios no: **0**
- Zelli V, Silvestri V, Valentini V, Bucalo A, Rizzolo P, Zanna I, Bianchi S, **Coppa A**, Giannini G, Cortesi L, Calistri D, Tibiletti MG, Fox SB, Fab K, Palli D, Ottini L *Transcriptome of Male Breast Cancer Matched with Germline Profiling Reveals Novel Molecular Subtypes with Possible Clinical Relevance.* **Cancers** (Basel). 2021 Sep 8;13(18):4515. doi:10.3390/cancers13184515. PMID:34572741  
[WOS] Journal Impact Factor 2021: **6,639** citatios no:**0**  
[Scopus] citatios no: **0**
- Barnes DR, Silvestri V, Leslie G, McGuffog L, Dennis J, Yang X, Adlard J, Agnarsson BA, Ahmed M, Aittomäki K, Andrulis IL, Arason A, Arnold N, Auber B, Azzollini J, Balmaña J, Barkardottir RB, Barrowdale D, Barwell J, Belotti M, Benitez J, Berthet P, Boonen SE, Borg Å, Bozsik A, Brady A, Brennan P, Brewer C, Brunet J, Bucalo A, Buys SS, Caldés T, Caligo MA, Campbell I, Cassingham H, Lotte Christensen L, Cini G, Claes KBM; GEMO Study Collaborators; EMBRACE Collaborators, Cook J, **Coppa A**, Cortesi L, Damante G....et al. *Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores.* **J Natl Cancer Inst.** 2021 Jul 28:djab147. doi: 10.1093/jnci/djab147. Online ahead of print  
[WOS] Journal Impact Factor 2021: **13,5** citatios no:**0**  
[Scopus] citatios no: **0**

- Belardinilli F, Pernazza A, Mahdavian Y, Cerbelli B, Bassi M, Gradilone A, **Coppa A**, Pignataro MG, Anile M, Venuta F, Della Rocca C, Giannini G, d'Amati G. *A multidisciplinary approach for the differential diagnosis between multiple primary lung adenocarcinomas and intrapulmonary metastases*. **Pathol Res Pract**. 2021 Apr;220:153387. doi: 10.1016/j.prp.2021.153387.  
[WOS] Journal Impact Factor 2021: **3,250** citations no: **0**  
[Scopus] citations no: **0**
- Nicolussi A, Belardinilli F, Ottini L, Petroni M, Capalbo C, Giannini G, **Coppa A**. A novel BRCA2 splice variant identified in a young woman. *Mol Genet Genomic Med*. 2020 Dec;8(12):e1513. doi: 10.1002/mgg3.1513 PMID:33159495 DOI: 10.1002/mgg3.1513  
[WOS] Journal Impact Factor 2020: **2.18** citations no: **0**  
[Scopus] citations no: **0**
- Pecorella I, **Coppa A**, Nicolussi A, Manganaro L, Fiorentin F, Palaia I, Muzii L. *CTNNB1 p.L31P mutation in an ovarian endometrioid carcinoma with synchronous uterine endometrioid carcinoma* **Pathol Res Pract**. 2020 Oct 18;216(12):153260. doi: 10.1016/j.prp.2020.153260. PMID: 33120166.  
[WOS] Journal Impact Factor 2020: **3,250** citations no: **0**  
[Scopus] citations no: **0**
- Belardinilli F, Capalbo C, Malapelle U, Pisapia P, Raimondo D, Milanetti E, Yasaman M, Liccardi C, Paci P, Sibilio P, Pepe F, Bonfiglio C, Mezi S, Magri V, **Coppa A**, Nicolussi A, Gradilone A, Petroni M, Di Giulio S, Fabretti F, Infante P, Coni S, Canettieri G, Troncone G, Giannini G. *Clinical multigene panel sequencing identifies distinct mutational association patterns in metastatic colorectal*. **Front Oncol**. 2020 May 7;10:560. doi: 10.3389/fonc.2020.00560. PMID: 32457828. **Selezionato**  
[WOS] Journal Impact Factor 2020: **6,24** citations no:-  
[Scopus] citations no: **5**
- Petroni M, Sahùn Roncero M, Ramponi V, Fabretti F, Nicolis Di Robilant V, Moretti M, Alfano V, Corsi A, De Panfilis S, Giubettini M, Di Giulio S, Capalbo C, Belardinilli F, **Coppa A**, Sardina F, Colicchia V, Pedretti F, Infante P, Cardinali B, Tessitore A, Canettieri G, De Smaele E, Giannini G. *SMO-M2 mutation does not support cell-autonomous Hedgehog activity in cerebellar granule cell precursors*. **Sci Rep**. 2019 Dec 23;9(1):19623. doi: 10.1038/s41598-019-56057-y. PMID: 31873117.  
[WOS] Journal Impact Factor 2019: **3,998** citations no:-  
[Scopus] citations no: **2**
- Nicolussi A, Belardinilli F, Silvestri V, Mahdavian Y, Valentini V, D'Inzeo S, Petroni M, Zani M, Ferraro S, Di Giulio S, Fabretti F, Fratini B, Gradilone A, Ottini L, Giannini G, **Coppa A**, Capalbo C. *Identification of novel BRCA1 large genomic rearrangements by a computational algorithm of amplicon-based Next-Generation Sequencing data*. **Peer J**. 2019 Nov 15;7:e7972. doi: 10.7717/peerj.7972. eCollection 2019. PMID: 31741787.  
[WOS] Journal Impact Factor 2019: **2,379** citations no: **1**  
[Scopus] citations no: **1**
- Rizzolo P, Silvestri V, Valentini V, Zelli V, Bucalo A, Zanna I, Bianchi S, Tibiletti MG, Russo A, Varesco L, Tedaldi G, Bonanni B, Azzollini J, Manoukian S, **Coppa A**, Giannini G, Cortesi L, Viel A, Montagna M, Peterlongo P, Radice P, Palli D, Ottini L. *Evaluation of CYP17A1 and CYP11B polymorphisms in male breast cancer risk*. **Endocr Connect**. 2019 Jul 1. pii: EC-19-0225.R1. doi: 10.1530/EC-19-0225. [Epub ahead of print] PMID: 31336362.  
[WOS] Journal Impact Factor 2019: **2,592** citations no: **2**  
[Scopus] citations no: **2**
- Nicolussi A, Belardinilli F, Mahdavian Y, Colicchia V, D'Inzeo S, Petroni M, Zani M, Ferraro S, Valentini V, Ottini L, Giannini G, Capalbo C and **Coppa A**. *Next-generation sequencing of BRCA1 and BRCA2 genes for rapid detection of germline mutations in hereditary breast/ovarian cancer* **Peer J**. 7 (2019): e6661 DOI 10.7717/peerj.6661 PMID: 31065452  
[WOS] Journal Impact Factor 2019: **2,379** citations no: **6**  
[Scopus] citations no: **9**
- Capalbo C, Belardinilli F, Raimondo D, Milanetti E, Malapelle U, Pisapia P, Magri V, Prete A, Pecorari S, Colella M, **Coppa A**, Bonfiglio C, Nicolussi A, Valentini V, Tessitore A, Cardinali B, Petroni M, Infante P, Santoni M, Filetti M, Colicchia V, Paci P, Mezi S, Longo F, Cortesi E, Marchetti P, Troncone G, Bellavia D, Canettieri G, Giannini G. *A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal Cancer*. **Cancers** (Basel). 2019 Jan 27;11(2). pii: E147. doi: 10.3390/cancers11020147. PMID: 30691222  
[WOS] Journal Impact Factor 2019: **6,126** citations no: **7**  
[Scopus] citations no: **7**

- Capalbo C, Belardinilli F, Filetti M, Parisi C, Petroni M, Colicchia V, Tessitore A, Santoni M, **Coppa A**, Giannini G, Marchetti P. *Effective treatment of a platinum-resistant cutaneous squamous cell carcinoma case by EGFR pathway inhibition.* **Mol Clin Oncol.** 2018 Jul;9(1):30-34. doi: 10.3892/mco.2018.1634. PMID: 29977536  
[WOS] Journal Impact Factor 2018: **0,5** citations no:**10**  
[Scopus] citations no: -
- Belardinilli F, Gradilone A, Gelibter A, Zani M, Occhipinti M, Ferraro S, Nicolazzo C, **Coppa A**, Giannini G. *Coexistence of three EGFR mutations in an NSCLC patient: A brief report.* **Int J Biol Markers.** 2018 Jun doi:10.1177/1724600818782200 PMID: 29945477 29977536  
[WOS] Journal Impact Factor 2018: **1,767** citations no:**2**  
[Scopus] citations no: **2**
- Petroni M, Sardina F, Infante P, Bartolazzi A, Locatelli E, Fabretti F, Di Giulio S, Capalbo C, Cardinali B, **Coppa A**, Tessitore A, Colicchia V, Sahùn Roncero M, Belardinilli F, Di Marcotullio L, Soddu S, Comes Franchini M, Petricci E, Gulino A, Giannini G. *MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN-driven tumors.* **Cell Death Dis.** 2018 Aug 30;9(9):895. doi: 10.1038/s41419-018-0924-z. PMID: 30166519  
[WOS] Journal Impact Factor 2018: **5,959** citations no:**23**  
[Scopus] citations no: **22**
- Rizzolo P, Silvestri V, Bucalo A, Zelli V, Valentini V, Catucci I, Zanna I, Masala G, Bianchi S, Spinelli AM, Tommasi S, Tibiletti MG, Russo A, Varesco A, **Coppa A**, Calistri D, Cortesi L, Viel V, Bonanni B, Azzollini J, Manoukian S, Montagna M, Radice P, Palli D, Peterlongo P and Ottini L. *Contribution of MUTYH variants to male breast cancer risk: results from a multicenter study in Italy.* **Frontiers in Oncology.** 4 December 2018 doi: 10.3389/fonc.2018.00583 PMID: 30564557  
[WOS] Journal Impact Factor 2018: **4,137** citations no: **14**  
[Scopus] citations no: **13**
- Silvestri V, Rizzolo P, Zelli V, Valentini V, Zanna I, Bianchi S, Tibiletti MG, Varesco L, Russo A, Tommasi S, **Coppa A**, Capalbo C, Calistri D, Viel A, Cortesi L, Manoukian S, Bonanni B, Montagna M, Palli D, Radice P, Peterlongo P, Ottini L. *A possible role of FANCM mutations in male breast cancer susceptibility: Results from a multicenter study in Italy.* **Breast.** 2017 Dec 26;38:92-97. doi: 10.1016/j.breast.2017.12.013 PMID: 29287190.  
[WOS] Journal Impact Factor 2017: **2,951** citations no: **14**  
[Scopus] citations no:**15**
- **Coppa A**, Nicolussi A, D'Inzeo S, Capalbo C, Belardinilli F, Colicchia V, Petroni M, Zani M, Ferraro S, Rinaldi C, Buffone A, Bartolazzi A, Screpanti I, Ottini L, Giannini G. *Optimizing the identification of risk-relevant mutations by multigene panel testing in selected hereditary breast/ovarian cancer families.* **Cancer Med.** 2017 Dec 22. doi: 10.1002/cam4.1251. [Epub ahead of print] PMID: 29271107  
[WOS] Journal Impact Factor 2017: **3,202** citations no:**12**  
[Scopus] citations no: **13**
- Colicchia V, Petroni M, Guarguaglini G, Sardina F, Sahùn-Roncero M, Carbonari M, Ricci B, Heil C, Capalbo C, Belardinilli F, **Coppa A**, Peruzzi G, Screpanti I, Lavia P, Gulino A, Giannini G. *PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma.* **Oncogene** 2017 Apr 10. doi: 10.1038/onc.2017.40. [Epub ahead of print] PMID: 28394338  
[WOS] Journal Impact Factor 2017: **6,854** citations no:**45**  
[Scopus] citations no:**50**
- Nicolussi A, D'Inzeo S, Capalbo C, Giannini G, **Coppa A**. *The role of peroxiredoxins in cancer.* **Mol Clin Oncol.** 2017 Feb;6(2):139-153. doi: 10.3892/mco.2017.1129 Epub 2017 Jan 10. PMID: 28357082  
[WOS] Journal Impact Factor 2017: **0,5** citations no: **88**  
[Scopus] citations no:-
- Silvestri V, Zelli V, Valentini V, Rizzolo P, Navazio AS, **Coppa A**, Agata S, Oliani C, Barana D, Castrignanò T, Viel A, Russo A, Tibiletti MG, Zanna I, Masala G, Cortesi L, Manoukian S, Azzollini J, Peissel B, Bonanni B, Peterlongo P, Radice P, Palli D, Giannini G, Chillemi G, Montagna M, Ottini L. *Whole-exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene.* **Cancer** 2016 Sep 20. doi: 10.1002/ncr.30337. [Epub ahead of print] PMID: 27648926.  
[WOS] Journal Impact Factor 2016: **6,07** citations no: **20**

[Scopus] citations no: **20**

- Prodosmo A, Buffone A, Mattioni M, Barnabei A, Persichetti A, De Leo A, Appetecchia M, Nicolussi A, **Coppa A**, Sciacchitano S, Giordano C, Pinnarò P, Sanguineti G, Strigari L, Alessandrini G, Facciolo F, Cosimelli M, Grazi GL, Corrado G, Vizza E, Giannini G, Soddu S. *Detection of ATM germline variants by the p53 mitotic centrosomal localization test in BRCA1/2-negative patients with early-onset breast cancer*. **J Exp Clin Cancer Res**. 2016 Sep 6;35(1):135.  
[WOS] Journal Impact Factor 2016: **5,89** citations no:**6+1**  
[Scopus] citations no: **5+1**
- Belardinilli F, Capalbo C, Buffone A, Petroni M, Colicchia V, Ferraro S, Zani M, Nicolussi A, D'Inzeo S, **Coppa A**, Screpanti I, Gulino A, Giannini G. *Validation of the Ion Torrent PGM sequencing for the prospective routine molecular diagnostic of colorectal cancer*. **Clin Biochem**. 2015 Sep;48(13-14):908-10. doi: 10.1016/j.clinbiochem.2015.04.003. Epub 2015 Apr 11 PMID: 25872148.  
[WOS] Journal Impact Factor 2015: **2,382** citations no:**18**  
[Scopus] citations no: **20**
- **Coppa A**, Buffone A, Capalbo C, Nicolussi A, D'Inzeo S, Belardinilli F, Colicchia V, Petroni M, Granato T, Midulla C, Zani M, Ferraro S, Screpanti I, Gulino A, Giannini G. *Novel and recurrent BRCA2 mutations in Italian breast/ovarian cancer families widen the ovarian cancer cluster region boundaries to exons 13 and 14*. **Breast Cancer Res Treat**. 2014 Dec;148(3):629-35. doi: 10.1007/s10549-014-3196-z. Epub 2014 Nov 14 PMID: 25395318.  
[WOS] Journal Impact Factor 2014: **3,940** citations no:**6**  
[Scopus] citations no: **7**
- Avitabile D, Ranieri D, Nicolussi A, D'Inzeo S, Capriotti AL, Genovese L, Proietti S, Cucina A, **Coppa A**, Samperi R, Bizzarri M, Laganà A, Torrisi MR. *Peroxiredoxin 2 nuclear levels are regulated by circadian clock synchronization in human keratinocytes*. **Int J Biochem Cell Biol**. 2014 Aug;53:24-34. doi: 10.1016/j.biocel.2014.04.024. Epub 2014 May 9 PMID: 24814289.  
[WOS] Journal Impact Factor 2014: **4,046** citations no:**17**  
[Scopus] citations no: **18**
- Capalbo C, Marchetti P, **Coppa A**, Calogero A, Anastasi E, Buffone A, Belardinilli F, Gulino M, Frati P, Catalano C, Cortesi E, Giannini G, Gulino A. *Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer: a case report*. **Cancer Biol Ther**. 2014 Jul;15(7):826-31. doi: 10.4161/cbt.28878. Epub 2014 Apr 22 PMID: 24755613.  
[WOS] Journal Impact Factor 2014: **3,072** citations no:**18**  
[Scopus] citations no: **17**
- Nicolussi A, D'Inzeo S, Mincione G, Buffone A, Di Marcantonio MC, Cotellese R, Cichella A, Capalbo C, Di Gioia C, Nardi F, Giannini G, **Coppa A**. *PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms*. **Int J Oncol**. 2014 Feb;44(2):548-56. doi: 10.3892/ijo.2013.2208. Epub 2013 Dec 5. PMID: 24316730.  
[WOS] Journal Impact Factor 2014: **3,025** citations no:**22**  
[Scopus] citations no: **21**
- D'Inzeo S, Nicolussi A, Nardi F, **Coppa A**. *Effects of the Smad4 C324Y mutation on thyroid cell proliferation*. **Int J Oncol**. 2013 Jun;42(6):1890-6. doi: 10.3892/ijo.2013.1908. Epub 2013 Apr 17 PMID: 23591524.  
[WOS] Journal Impact Factor 2013: **2,773** citations no:**2**  
[Scopus] citations no: **2**
- Donini CF, Di Zazzo E, Zuchegna C, Di Domenico M, D'Inzeo S, Nicolussi A, Avvedimento EV, Coppa A, Porcellini A. *The p85α regulatory subunit of PI3K mediates cAMP-PKA and retinoic acid biological effects on MCF7 cell growth and migration*. **Int J Oncol**. 2012 May;40(5):1627-35. doi: 10.3892/ijo.2012.1383. Epub 2012 Feb 21 PMID: 22366926.  
[WOS] Journal Impact Factor 2012: **2,657** citations no:**19**  
[Scopus] citations no: **20**
- D'Inzeo S, Nicolussi A, Donini CF, Zani M, Mancini P, Nardi F, **Coppa A**. *A novel human Smad4 mutation is involved in papillary thyroid carcinoma progression*. **Endocr Relat Cancer**. 2012 Jan 9;19(1):39-55. doi: 10.1530/ERC-11-0233. Print 2012 Feb. PMID: 22109972.  
[WOS] Journal Impact Factor 2012: **5,261** citations no:**18**



[Scopus] citations no: **19**

- Anastasi E, Granato T, **Coppa A**, Manganaro L, Giannini G, Comploj S, Frati L, Midulla C. *HE4 in the Differential Diagnosis of a Pelvic Mass: A Case Report.* **Int J Mol Sci.** 2011; Jan 18;12(1):627-32. doi: 10.3390/ijms12010627 PMID: 21340004.  
[WOS] Journal Impact Factor 2011: **2,598** citations no: **8**  
[Scopus] citations no: **9**
- Mincione G, Di Marcantonio MC, Tarantelli C, D'Inzeo S, Nicolussi A, Nardi F, Donini CF, **Coppa A.** *EGF and TGF- $\beta$ 1 Effects on Thyroid Function.* **J Thyroid Res.** 2011; 2011:431718. doi: 10.4061/2011/431718. Epub 2011 Jun 13 PMID: 21760980.  
[WOS] Journal Impact Factor 2011: **1,78** citations no: **0**  
[Scopus] citations no: **21**
- D'Inzeo S, Nicolussi A, Ricci A, Mancini P, Porcellini A, Nardi F, **Coppa A.** *Role of reduced expression of SMAD4 in papillary thyroid carcinoma.* **J Mol Endocrinol.** 2010 Oct;45(4):229-44. doi: 10.1677/JME-10-0044. PMID: 20685810  
[WOS] Journal Impact Factor 2010: **3,628** citations no: **18**  
[Scopus] citations no: **21**
- Picarelli A, Sabbatella L, Di Tola M, Silano M, Nicolussi A, D'Inzeo S, **Coppa A.** *Nuclear fluorescence serum reactivity on monkey oesophagus: a new antibody for the follow-up of coeliac disease?* **Clin Exp Immunol.** 2010 Sep;161(3):417-25 doi: 10.1111/j.1365-2249.2010.04184.x PMID: 20529089.  
[WOS] Journal Impact Factor 2010: **3,134** citations no: **2**  
[Scopus] citations no: **1**
- De Gregorio G, **Coppa A**, Cosentino C, Ucci S, Messina S, Nicolussi A, D'Inzeo S, Di Pardo A, Avvedimento EV, Porcellini A. *The p85 regulatory subunit of PI3K mediates TSH-cAMP-PKA growth and survival signals.* **Oncogene.** 2007 Mar 29;26(14):2039-47 doi: 10.1038/sj.onc.1210011 PMID: 17043656.  
[WOS] Journal Impact Factor 2007: **6,44** citations no: **42**  
[Scopus] citations no: **44**
- Nicolussi A, D'Inzeo S, Gismondi A, **Coppa A.** *Reduction of invasive potential in K-ras-transformed thyroid cells by restoring of TGF-beta pathway.* **Clin Exp Metastasis.** 2006;23(5-6):237-48 doi: 10.1007/s10585-006-9023-0 PMID: 17086361.  
[WOS] Journal Impact Factor 2006: **1,986** citations no: **7**  
[Scopus] citations no: **7**
- Lazzereschi D, Nardi F, Turco A, Ottini L, D'Amico C, Mariani-Costantini R, Gulino A, **Coppa A.** *A complex pattern of mutations and abnormal splicing of Smad4 is present in thyroid tumours.* **Oncogene** 2005 Aug 11;24(34):5344-54 doi: 10.1038/sj.onc.1208603. PMID: 15940269.  
[WOS] Journal Impact Factor 2005: **6,872** citations no: **38**  
[Scopus] citations no: **40**
- Nicolussi A, D'Inzeo S, Santulli M, Colletta G, **Coppa A.** *TGF-beta control of rat thyroid follicular cells differentiation.* **Mol Cell Endocrinol.** 2003 Sep 30;207(1-2): 1-11. doi: 10.1016/s0303-7207(03)00238-7 PMID: 12972178.  
[WOS] Journal Impact Factor 2003: **2,637** citations no: **38**  
[Scopus] citations no: **42**
- Napolitano G, Montani V, Giuliani C, Di Vincenzo S, Bucci I, Todisco V, Laglia G, **Coppa A**, Singer DS, Nakazato M, Kohn LD, Colletta G, Monaco F. *Transforming growth factor-beta1 down-regulation of major histocompatibility complex class I in thyrocytes: coordinate regulation of two separate elements by thyroid-specific as well as ubiquitous transcription factors.* **Endocrinology** 2000 Apr;14(4):486-505. doi: 10.1210/mend.14.4.0454 PMID: 10770487.  
[WOS] Journal Impact Factor 2000: **4,79** citations no: **23**  
[Scopus] citations no: **25**
- Turco A, Scarpa S, **Coppa A**, Baccheschi G, Palumbo C, Leonetti C, Zupi G, Colletta G. *Increased TGFbeta type II receptor expression suppresses the malignant phenotype and induces differentiation of human neuroblastoma cells.* **Exp Cell Res.** 2000 Feb 25;255(1):77-85 doi: 10.1006/excr.1999.4750 PMID: 10666336.  
[WOS] Journal Impact Factor 2000: **3,860** citations no: **13**

[Scopus] citations no: **15**

- Baccante G, Mincione G, Di Febbo C, **Coppa A**, Angelucci D, Lapenna D, Cucurullo F, Colletta G, Porreca E. *Increased type II transforming growth factor-beta receptor expression in liver cells during cholesterol challenge. Atherosclerosis* 2000 Sep;152(1):51-7 doi: 10.1016/s0021-9150(99)00449-9 PMID: 10996339.  
[WOS] Journal Impact Factor 2000: **3,386** citations no:2  
[Scopus] citations no: **2**
- Turco A, **Coppa A**, Aloe S, Baccheschi G, Morrone S, Zupi G, Colletta G. *Overexpression of transforming growth factor beta-type II receptor reduces tumorigenicity and metastatic potential of K-ras-transformed thyroid cells. Int J Cancer.* 1999 Jan 5;80(1):85-91 doi: 10.1002/(sici)1097-0215(19990105)80:1<85::aid-ijc17>3.0.co;2-p PMID: 9935236.  
[WOS] Journal Impact Factor 1998: **3,545** citations no:28  
[Scopus] citations no: **42**
- Farina AR, **Coppa A**, Tiberio A, Tacconelli A, Turco A, Colletta G, Gulino A, Mackay AR. *Transforming growth factor-beta1 enhances the invasiveness of human MDA-MB-231 breast cancer cells by up-regulating urokinase activity. Int J Cancer.* 1998 Mar 2;75(5):721-30 doi: 10.1002/(sici)1097-0215(19980302)75:5<721::aid-ijc10>3.0.co;2-9.  
[WOS] Journal Impact Factor 1998: **3,283** citations no:114  
[Scopus] citations no: **115**
- Lazzereschi D, Mincione G, **Coppa A**, Ranieri A, Turco A, Baccheschi G, Pelicano S, Colletta G. *Oncogenes and antioncogenes involved in human thyroid carcinogenesis. J Exp Clin Cancer Res.* 1997 Sep;16(3):325-32. PMID: 9387909.  
[WOS] Journal Impact Factor 1997: **0,232** citations no:14  
[Scopus] citations no: **17**
- Lazzereschi D, **Coppa A**, Mincione G, Lavitrano M, Fragomele F, Colletta G. *The phosphatase inhibitor okadaic acid stimulates the TSH-induced G1-S phase transition in thyroid cells. Exp Cell Res.* 1997 Aug 1;234(2):425-33. doi: 10.1006/excr.1997.3627 PMID: 9260913.  
[WOS] Journal Impact Factor 1997: **3,056** citations no:14  
[Scopus] citations no: **14**
- **Coppa A**, Mincione G, Lazzereschi D, Ranieri A, Turco A, Lucignano B, Scarpa S, Ragano-Caracciolo M, Colletta G. *Restored expression of transforming growth factor beta type II receptor in k-ras-transformed thyroid cells, TGF beta-resistant, reverts their malignant phenotype. J Cell Physiol.* 1997 Aug;172(2):200-8 doi: 10.1002/(SICI)1097-4652(199708)172:2<200::AID-JCP7>3.0.CO;2-S PMID: 9258341  
[WOS] Journal Impact Factor 1997: **2,458** citations no:26  
[Scopus] citations no: **25**
- Scarpa S, **Coppa A**, Ragano-Caracciolo M, Mincione G, Giuffrida A, Modesti A, Colletta G. *Transforming growth factor beta regulates differentiation and proliferation of human neuroblastoma. Exp Cell Res.* 1996 Nov 25;229(1):147-54 doi: 10.1006/excr.1996.0352 PMID: 8940258  
[WOS] Journal Impact Factor 1996: **3,056** citations no:26  
[Scopus] citations no: **27**
- **Coppa A**, Mincione G, Mammarella S, Ranieri A, Colletta G. *Epithelial rat thyroid cell clones, escaping from transforming growth factor beta negative growth control, are still inhibited by this factor in the ability to trap iodide. Cell Growth Differ.* 1995 Mar;6(3):281-90 PMID: 7794796.  
[WOS] Journal Impact Factor 1995: **4,179** citations no: **30**  
[Scopus] citations no: **30**
- Vajro P, Fontanella A, De Vincenzo A, Lettera P, Greco L, **Coppa A**, D'Armiento M. *Monitoring of serum alpha-fetoprotein levels in children with chronic hepatitis B virus infection. J Pediatr Gastroenterol Nutr.* 1991 Jan;12(1):27-32  
[WOS] Journal Impact Factor 1991: **1.294** citations no:3  
[Scopus] citations no: -
- Di Carlo A, Mariano A, **Coppa A**, Macchia V, Maiuri F, Iaconetta G, D'Andrea F. *Epidermal growth factor receptor and tissue tumor markers in human intracranial neoplasms. J Neurosurg Sci.* 1990 Jul-Dec;34(3-4):181-5, ISSN 00264881.  
[WOS] Journal Impact Factor 1990: **2.87** citations no:-

[Scopus] citations no: **2**

- La Montagna G, **Coppa A**, Bencivenga T, Tirri G. *Serum gastrin, fasting and after stimulation, in systemic sclerosis. Scand J Rheumatol.* 1989;18(5):329-31 doi10.3109/03009748909095038, ISSN 03009742.  
[WOS] Journal Impact Factor 1989: **0.855** citations no: **1**  
[Scopus] citations no:**1**
- Macchia V, Mariano A, Cavalcanti M, **Coppa A**, Cecere C, Fraioli G, Elia S, Ferrante G. *Tumor markers and lung cancer: correlation between serum and bronchial secretion levels of CEA, TPA, CanAg CA-50, NSE and ferritin. Int J Biol Markers.* 1987 Sep-Dec;2(3):151-6 doi 10.1177/172460088700200303, ISSN 03936155.  
[WOS] Journal Impact Factor 1987: **2.87** citations no:-  
[Scopus] citations no: **21**

Roma, 8-12-2021

Anna Coppa

